Do analysts prefer IMA or ALVR?

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 583.96%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImageneBio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, IMA or ALVR?

ImageneBio has higher revenue and earnings than AlloVir. ImageneBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio $800K 60.16 -$45.35M -$4.58 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is IMA or ALVR more profitable?

ImageneBio's return on equity of -38.99% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.99% -34.84% AlloVir N/A -71.03% -61.27%

Do analysts prefer BKHA or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, BKHA or ALVR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BKHA or ALVR more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A AlloVir N/A -71.03% -61.27%

Do analysts recommend ANVS or ALVR?

Annovis Bio presently has a consensus target price of $12.00, suggesting a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Annovis Bio is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, ANVS or ALVR?

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.79 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is ANVS or ALVR more profitable?

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -685.98% -258.77% AlloVir N/A -71.03% -61.27%

Do analysts recommend ALVR or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher earnings and valuation, ALVR or INMB?

INmune Bio has higher revenue and earnings than AlloVir. INmune Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AlloVir N/A N/A -$190.42M -$20.23 N/A INmune Bio $50K 932.40 -$45.93M -$0.67 N/A

Is ALVR or INMB more profitable?

AlloVir's return on equity of -71.03% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets AlloVir N/A -71.03% -61.27% INmune Bio N/A -82.87% -62.23%

Do analysts prefer YARW or ALVR?

Yarrow Bioscience presently has a consensus price target of $58.00, suggesting a potential upside of 211.83%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Yarrow Bioscience is more favorable than AlloVir. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yarrow Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

AlloVir (ALVR) Competitors

$2.23 -0.03 (-1.33%)

As of 10/13/2026

Compare

ALVR vs. IMA, BKHA, ANVS, INMB, and YARW

Should you buy AlloVir stock or one of its competitors? AlloVir's main competitors and comparable companies include ImageneBio (IMA), Black Hawk Acquisition (BKHA), Annovis Bio (ANVS), INmune Bio (INMB), and Yarrow Bioscience (YARW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AlloVir compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

ImageneBio has higher revenue and earnings than AlloVir. ImageneBio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	60.16	-$45.35M	-$4.58	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

ImageneBio has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, indicating that its stock price is 37% less volatile than the broader market.

ImageneBio currently has a consensus price target of $29.00, suggesting a potential upside of 583.96%. Given ImageneBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImageneBio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ImageneBio's return on equity of -38.99% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, ImageneBio had 2 more articles in the media than AlloVir. MarketBeat recorded 2 mentions for ImageneBio and 0 mentions for AlloVir. ImageneBio's average media sentiment score of 1.38 beat AlloVir's score of 0.00 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Positive
AlloVir	Neutral

Summary

ImageneBio beats AlloVir on 13 of the 15 factors compared between the two stocks.

How does AlloVir compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Black Hawk Acquisition has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Black Hawk Acquisition's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Black Hawk Acquisition had 8 more articles in the media than AlloVir. MarketBeat recorded 8 mentions for Black Hawk Acquisition and 0 mentions for AlloVir. Black Hawk Acquisition's average media sentiment score of 0.27 beat AlloVir's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Black Hawk Acquisition	Neutral
AlloVir	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Black Hawk Acquisition beats AlloVir on 5 of the 8 factors compared between the two stocks.

How does AlloVir compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Annovis Bio presently has a consensus target price of $12.00, suggesting a potential upside of 1,037.44%. Given Annovis Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Annovis Bio is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Annovis Bio has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 15.9% of Annovis Bio shares are held by insiders. Comparatively, 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annovis Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

AlloVir's return on equity of -71.03% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-685.98%	-258.77%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Annovis Bio's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
AlloVir	Neutral

Summary

Annovis Bio beats AlloVir on 6 of the 11 factors compared between the two stocks.

How does AlloVir compare to INmune Bio?

AlloVir (NASDAQ:ALVR) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

AlloVir's return on equity of -71.03% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AlloVir	N/A	-71.03%	-61.27%
INmune Bio	N/A	-82.87%	-62.23%

In the previous week, INmune Bio had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for INmune Bio and 0 mentions for AlloVir. INmune Bio's average media sentiment score of 0.91 beat AlloVir's score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
AlloVir	Neutral
INmune Bio	Positive

AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

INmune Bio has higher revenue and earnings than AlloVir. INmune Bio is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A
INmune Bio	$50K	932.40	-$45.93M	-$0.67	N/A

66.1% of AlloVir shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

INmune Bio beats AlloVir on 8 of the 12 factors compared between the two stocks.

How does AlloVir compare to Yarrow Bioscience?

Yarrow Bioscience (NASDAQ:YARW) and AlloVir (NASDAQ:ALVR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Yarrow Bioscience presently has a consensus price target of $58.00, suggesting a potential upside of 211.83%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Yarrow Bioscience is more favorable than AlloVir.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

AlloVir has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. AlloVir's return on equity of -71.03% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-84.40%	-77.68%
AlloVir	N/A	-71.03%	-61.27%

In the previous week, Yarrow Bioscience had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Yarrow Bioscience and 0 mentions for AlloVir. Yarrow Bioscience's average media sentiment score of 0.91 beat AlloVir's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Yarrow Bioscience	Positive
AlloVir	Neutral

Yarrow Bioscience has higher revenue and earnings than AlloVir. Yarrow Bioscience is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	87.13	-$26.48M	-$14.64	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Yarrow Bioscience has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Yarrow Bioscience beats AlloVir on 10 of the 14 factors compared between the two stocks.

Get AlloVir News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVR vs. The Competition

Export

Metric	AlloVir	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.25M	$3.90B	$7.28B	$12.92B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	-0.11	12.49	275.28	25.28
Price / Sales	N/A	1,151.22	562.38	78.55
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.08	16.55	10.52	5.92
Net Income	-$190.42M	-$22.69M	$3.50B	$381.04M
7 Day Performance	-16.17%	-6.66%	-4.32%	-4.41%
1 Month Performance	-34.02%	-14.41%	-8.66%	-7.30%
1 Year Performance	-53.15%	5.91%	1.94%	-5.04%

AlloVir Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVR AlloVir	N/A	$2.23 -1.3%	N/A	-49.2%	$11.25M	N/A	N/A	110	High Trading Volume
IMA ImageneBio	3.3572 of 5 stars	$4.61 +0.2%	$29.00 +529.1%	-44.9%	$52.32M	$800K	N/A	18	Positive News
BKHA Black Hawk Acquisition	N/A	$12.53 +2.0%	N/A	+10.4%	$51.98M	N/A	N/A	2	Trending News Gap Down Trading Halted
ANVS Annovis Bio	1.7461 of 5 stars	$1.22 +3.0%	$12.00 +887.7%	-35.5%	$51.86M	N/A	N/A	7
INMB INmune Bio	0.61 of 5 stars	$1.87 -0.3%	N/A	-8.2%	$51.78M	$50K	N/A	21	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AlloVir (ALVR) Competitors